Compare AKBA & KRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | KRUS |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 849.5M |
| IPO Year | 2014 | 2019 |
| Metric | AKBA | KRUS |
|---|---|---|
| Price | $1.43 | $72.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $6.25 | ★ $81.50 |
| AVG Volume (30 Days) | ★ 2.9M | 378.9K |
| Earning Date | 03-12-2026 | 01-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $225,071,000.00 | ★ $291,762,000.00 |
| Revenue This Year | $52.38 | $19.23 |
| Revenue Next Year | $22.45 | $20.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.49 | 16.31 |
| 52 Week Low | $1.30 | $40.03 |
| 52 Week High | $4.08 | $95.98 |
| Indicator | AKBA | KRUS |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 67.24 |
| Support Level | $1.30 | $70.48 |
| Resistance Level | $1.41 | $77.00 |
| Average True Range (ATR) | 0.07 | 4.77 |
| MACD | -0.00 | 0.93 |
| Stochastic Oscillator | 37.88 | 79.19 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.